We selected F98 glioma cells with the lowest endogenous MCT4 mRNA expression for genetic manipulation so that genetically induced MCT4 overexpression would not be disturbed by already high endogenous MCT4 expression levels. The gene discussed is SLC16A3; the disease is glioma.